Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Patients with plasma cell dyscrasias (PCD), including multiple myeloma, AL amyloidosis, and monoclonal gammopathy of renal significance (MGRS), face a high burden of end-stage kidney disease (ESKD), limiting survival and quality of life. While kidney transplantation offers potential benefits, it is underutilized due to high risk of recurrence and historically poor outcomes. A multidisciplinary panel of transplant nephrologists, hematologists/oncologists, and pathologists convened to evaluate contemporary evidence and evolving strategies in kidney transplant for PCD-ESKD.
